EGFR and colorectal carcinoma: PIK3CA mutations, which occur in 10–18% of CRC cases, activate the PI3K/AKT pathway, thereby conferring resistance to anti-EGFR mAbs.269 Mutations in PIK3CA exons 9 and 20, which constitute the majority of these mutations, lead to pathway activation.